Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

SyncAV Post-Market Trial

NCT04100148 · View on ClinicalTrials.gov ↗

Study Summary

The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ventricular (LV) reverse remodeling.

Conditions Studied

Interventions

  • DEVICE SyncAV programmed ON
  • DEVICE Fixed AV delay

Study Locations (20)

California

  • Comprehensive Cardiovascular — Bakersfield
  • Cardiovascular Consultants Heart Center — Fresno
  • USC University Hospital — Los Angeles

New Jersey

  • Deborah Heart & Lung Center — Browns Mills
  • Cardiovascular Associates of the Delaware Valley — Haddon Heights
  • Lourdes Cardiology Services — Voorhees Township

Arizona

  • Arizona Cardiovascular Research Center — Phoenix
  • HonorHealth — Scottsdale

Florida

  • Shands at the University of Florida — Gainesville
  • Heart Rhythm Solutions — Hollywood

Georgia

  • Piedmont Heart Institute — Atlanta
  • Emory University Hospital — Atlanta

Alabama

  • Heart Center Research, LLC. — Huntsville

Colorado

  • Colorado Heart & Vascular, P.C. — Lakewood

Iowa

  • Iowa Heart Center — West Des Moines

Trial Details

FieldValue
Enrollment Target 1,686 participants
Start Date 2019-10-03
Est. Completion 2026-06-30
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04100148

The ClinicalTrials.gov registry entry for NCT04100148 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,686 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 2 interventions — of which SyncAV programmed ON is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04100148 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, New Jersey, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04100148 about?

NCT04100148 is a clinical study titled "SyncAV Post-Market Trial". The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ...

What is the current status of trial NCT04100148?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,686 participants. The study started on 2019-10-03. Estimated completion is 2026-06-30.

What conditions does trial NCT04100148 study?

This clinical trial studies the following conditions: Congestive Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04100148?

The interventions under investigation include: SyncAV programmed ON (DEVICE), Fixed AV delay (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04100148?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04100148 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial